The U.S. Food and Drug Administration on [April 26] announced its approval of the first U.S. facility for production of genetically engineered salmon.
However, an “import alert” for genetically engineered salmon remains in place, preventing U.S. production for now.
“With the facility now approved, commercial production of AquAdvantage Salmon awaits only official labeling guideline by the FDA,” AquaBounty Technologies, Maynard, Mass., said in a news release.
AquaBounty Technologies purchased for $14 million last year a defunct fish farm in Albany [Indiana] where perch, trout and salmon had been raised.
AquAdvantage Salmon is an Atlantic salmon that the company says has been “enhanced to grow to market size in about half the time of a traditional farmed Atlantic salmon.” It is grown only in land-based contained facilities using a sterile, all-female population.
The Indiana facility as currently configured has a production capacity of 1,200 tons per year and was designed to allow significant expansion, the company said.
Here is the announcement from the FDA
Read full, original post: FDA OKs first U.S. genetically engineered salmon facility, at Albany